Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Deafness with labyrinthine aplasia, microtia, and microdontia (LAMM) is a genetic transmission deafness syndrome.
Features include always present findings: Microdontia, Delayed gross motor development, Profound sensorineural hearing impairment, and Aplasia of the inner ear and others; and very common findings: Anteverted ears. 15 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 2 | Long face, Peg-shaped maxillary lateral incisors |
Skin | 1 | Skin tags |
Brain and nerves | 1 | Delayed gross motor development |
Muscles | 1 | Delayed gross motor development |
Ears | 1 | Profound sensorineural hearing impairment |
Age of onset: at birth.
Labyrinthine aplasia, microtia, and microdontia (LAMM syndrome) was originally described by . Since then more than 60 individuals with homozygous and compound heterozygous FGF3 pathogenic variants from more than 20 families (consanguineous and nonconsanguineous) have been reported . Age at diagnosis is typically age 50 years or younger (range: 1 month to 50 years). Profound congenital sensorineural deafness is bilateral in all individuals reported to date. Most have bilateral complete labyrinthine aplasia, some have unilateral complete labyrinthine aplasia and visible but severely malformed inner ear structures in the other ear, and a few have some inner ear structure present bilaterally .
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
FGF3 encodes fibroblast growth factor 3 (239 aa). Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal ear development Highest expression in Brain Cerebellar Hemisphere (25.1 TPM) and Brain Cerebellum (25.1 TPM).
Deafness with labyrinthine aplasia, microtia, and microdontia is caused by mutations in the FGF3 gene on chromosome 11.
The FGF3 protein participates in Activation of anterior HOX genes in hindbrain development during early embryogenesis pathway.
FGF3 is classified as a druggable target (Clinically Actionable, Druggable Genome, and Growth Factor categories) with score 2.2.
The variant is associated with a less severe phenotype than the other FGF3 pathogenic variants .
Microtia was not observed in eight of 11 individuals homozygous for p.Arg95Trp; in contrast, none of the persons reported with other pathogenic variants had normal-appearing external ears.
Inner ear structures were identified in seven of 20 individuals homozygous for p.Arg95Trp; in contrast, persons reported with other pathogenic variants had either no inner ear components or primitive vesicle-like structures.
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
The diagnosis of congenital deafness with labyrinthine aplasia, microtia, and microdontia (LAMM syndrome) should be suspected in individuals with the following:
Profound congenital sensorineural deafness
Severe inner ear anomalies diagnosed by CT scan or MRI of the inner ear. The most common inner ear anomaly is complete labyrinthine aplasia with no recognizable structure in the inner ear (also referred to as Michel aplasia).
Microtia with shortening of the upper part of the auricles (also referred to as type I microtia)
Microdontia (small teeth) with widely spaced teeth
Some individuals may also show gross motor developmental delay during infancy (presumably due to the absence of vestibular system) accompanied by additional features that include:
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
Table 2.
Other Genes of Interest in the Differential Diagnosis of LAMM Syndrome
Gene(s) | DiffDx Disorder | MOI | Clinical Features of DiffDx Disorder
Overlapping w/LAMM syndrome | Distinguishing from LAMM syndrome
FGF10
FGFR2
| Lacrimo-auriculo-dento-digital (LADD) syndrome (OMIM 149730) | AD | • Hearing loss
Dental anomalies
| • Aplasia, atresia, or hypoplasia of the lacrimal salivary systems
Cup-shaped ears
Digital (particularly thumb) anomalies
EYA1
SIX1 | Branchiootorenal spectrum disorder1 | AD | Hearing loss | • Branchial fistulae cysts
Renal malformations
KMT2D
| Kabuki syndrome | ADXL | • Hearing loss
Genetic testing for FGF3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for deafness with labyrinthine aplasia, microtia, and microdontia has been reported in the published literature.
No approved treatments are currently available for deafness with labyrinthine aplasia, microtia, and microdontia. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with congenital deafness with labyrinthine aplasia, microtia, and microdontia (LAMM syndrome), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia
System/Concern | Evaluation | Comment |
|---|---|---|
ENT | CT /or MRI of temporal bones | Evaluate inner ear anomalies |
Hearing | Audiologic eval | Evaluate for sensorineural hearing loss |
Dental | Dental eval | Evaluate for dental anomalies |
Renal | Consider renal ultrasound. | Evaluate for kidney anomalies incl unilateral stenosis of uretero-pelvic junction |
Other | Consultation w/clinical geneticist /or genetic counselor | Ideally, the team evaluating and treating a deaf individual should include an otolaryngologist with expertise in the management of early-childhood otologic disorders, an audiologist experienced in the assessment of hearing loss in children, a clinical geneticist, and a pediatrician. |
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
Noise exposure is a well-recognized environmental cause of hearing loss. Since this risk can be minimized by avoidance, individuals with LAMM syndrome and a residual cochlea should be counseled appropriately. Because of the high risk for disorientation when submerged in water, swimming needs to be undertaken with caution.
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
View trials for deafness with labyrinthine aplasia, microtia, and microdontia
Table 4.
Recommended Surveillance for Individuals with Deafness with Congenital Labyrinthine Aplasia, Microtia, and Microdontia
System/Concern | Evaluation | Frequency
| ENT eval | Annually
| Ophthalmologic eval
| Dental eval | As neeeded
Yearly evaluations by the multidisciplinary team mentioned in is appropriate.
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
Phenotype severity distribution: 6 always present features, 1 very common feature, 3 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for deafness with labyrinthine aplasia, microtia, and microdontia.
121 publications have been identified in PubMed for deafness with labyrinthine aplasia, microtia, and microdontia. Research spans Review / Meta-Analysis (67%), Basic Science / Preclinical (15%), and Epidemiology / Natural History (6%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 81 | 67% |
Laboratory research | 18 | 15% |
Disease patterns and progression | 7 | 6% |
Patient case studies | 6 | 5% |
Other research | 4 | 3% |
Testing and diagnosis research | 4 | 3% |
Clinical study results | 1 | 1% |
Buel KL (2026). [PMID: 41569909](https://pubmed.ncbi.nlm.nih.gov/41569909/). *FP Essent*. [Review / Meta-Analysis]
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Graafen L (2026). [PMID: 41831046](https://pubmed.ncbi.nlm.nih.gov/41831046/). *J Clin Immunol*. [Diagnostic / Biomarker]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Gebhardt C (2025). [PMID: 40590899](https://pubmed.ncbi.nlm.nih.gov/40590899/). *Z Rheumatol*. [Review / Meta-Analysis]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Paller AS (2025). [PMID: 40184496](https://pubmed.ncbi.nlm.nih.gov/40184496/). *Br J Dermatol*. [Review / Meta-Analysis]
Zoref-Lorenz A (2025). [PMID: 39656557](https://pubmed.ncbi.nlm.nih.gov/39656557/). *Leuk Lymphoma*. [Review / Meta-Analysis]
Ma R (2025). [PMID: 40992234](https://pubmed.ncbi.nlm.nih.gov/40992234/). *J Clin Anesth*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 6:58 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
| • Skeletal anomalies
Typical facial features
Dermatoglyphic abnormalities
Congenital heart defects
Mild-to-moderate ID
| Townes-Brocks syndrome | AD | • Microtia
Source: GeneReviews — "Congenital Deafness with Labyrinthine Aplasia, Microtia, and Microdontia"
Recommended Surveillance for Individuals with Deafness with Congenital Labyrinthine Aplasia, Microtia, and Microdontia System/Concern | Evaluation | Frequency |
Deafness | ENT eval | Annually Strabismus |
Dental | Dental eval | As neeeded Yearly evaluations by the multidisciplinary team mentioned in is appropriate. Noise exposure is a well-recognized environmental cause of hearing loss. Since this risk can be minimized by avoidance, individuals with LAMM syndrome and a residual cochlea should be counseled appropriately. |